Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
WITHDRAWN
NCT03902067
PHASE1

UC-MSC Transplantation for Left Ventricular Dysfunction After AMI

Sponsor: Shanghai Life Science & Technology

View on ClinicalTrials.gov

Summary

A pilot study to evaluate the safety and feasibility of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction by catheter transplantation

Official title: Safety and Efficacy Evaluation of Umbilical Cord Mesenchymal Stem Cells Transcatheter Transplantation to Treat Left Ventricular Dysfunction After Acute Myocardial Infarction

Key Details

Gender

All

Age Range

50 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

0

Start Date

2024-12-01

Completion Date

2025-12-31

Last Updated

2026-05-11

Healthy Volunteers

No

Interventions

BIOLOGICAL

UC-MSC

0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU, at the concentration of 2x10(7) cells/ml.

BIOLOGICAL

Control Group

Routine treatment without catheter infusion

Locations (1)

Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Shanghai, Shanghai Municipality, China